NCT04794868View on ClinicalTrials.gov

PreDiction and Validation of Clinical CoursE of Coronary Artery DiSease With CT-Derived Non-Invasive HemodYnamic Phenotyping and Plaque Characterization (DESTINY Study)

CompletedOBSERVATIONAL
Enrollment

356

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Acute Coronary SyndromeIschemic Heart Disease
Interventions
DIAGNOSTIC_TEST

CCTA-derived high risk plaque characteristics

Presence of CCTA-derived high risk plaque characteristics

DIAGNOSTIC_TEST

CFD-derived hemodynamic parameters

CFD-derived hemodynamic parameters

Trial Locations (2)

Unknown

Shanghai Institute of Cardiovascular Diseases, Shanghai

06351

Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

Elucid Bioimaging Inc.

INDUSTRY

collaborator

Shanghai Institute of Cardiovascular Diseases

OTHER

lead

Samsung Medical Center

OTHER

NCT04794868 - PreDiction and Validation of Clinical CoursE of Coronary Artery DiSease With CT-Derived Non-Invasive HemodYnamic Phenotyping and Plaque Characterization (DESTINY Study) | Biotech Hunter | Biotech Hunter